M.D. Anderson to Hold Conference in Spanish

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

HOUSTON--The University of Texas M.D. Anderson Cancer Center will hold its second medical oncology conference in Spanish on May 22-24, 1996. The educational conference will bring together physicians from Spain and Latin American with the M.D. Anderson faculty, said Richard Pazdur, MD, associate professor of medicine and co-director of the conference along with Alejandro Preti, MD, assistant professor of medicine.

HOUSTON--The University of Texas M.D. Anderson Cancer Center willhold its second medical oncology conference in Spanish on May22-24, 1996. The educational conference will bring together physiciansfrom Spain and Latin American with the M.D. Anderson faculty,said Richard Pazdur, MD, associate professor of medicine and co-directorof the conference along with Alejandro Preti, MD, assistant professorof medicine.

"I think M.D. Anderson is unique in that it has such a diversegroup of Spanish-speaking faculty, both native speakers and thosewho learned the language along the way," Dr. Pazdur saidin an interview. Most of the speakers are M.D. Anderson faculty.In addition, physicians from Spain have been invited to discusstheir research work at a symposium to be held in conjunction withthe conference.

ASCO Findings Will Be Reviewed

The meeting will also provide an opportunity for a discussionof studies presented at the 1996 American Society of ClinicalOncology (ASCO) meeting, to put new findings into the contextof existing therapies, Dr. Pazdur said. He expects between 50and 100 physicians to attend the conference.

Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content